Fermiscan Holdings Share Price - FER, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(ASX:FER, FER.AX)

Fermiscan Holdings
www.fermiscan.com.au/irm/content/home.html

Description

Fermiscan Holdings (ASX: FER) is focused on a non-invasive diagnostic test for the detection of breast cancer.

News

All News ►

Recent Sector News

Medical Australia completes milestone first animal stem cell treatments in U.K.

The TUTAVet animal stem cell therapy has substantial commercial upside for Medical Australia. Following the completion of the first two procedures in the U.K. the company has generated strong interest from veterinary surgeons keen to trial the technology.
Medical Australia secures first mover advantage in Europe with animal stem cell therapy

Mark Donnison, managing director of Medical Australia, told Proactive Investors today the roll out of a new unique regenerative animal stem cell therapy offering in Europe presents the company with three potential revenue streams.
Medical Australia boosts FY2012 revenue by A$1.5m with new supply agreements

New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond.
Circadian Technologies moves into clinical development phase on approval of IND for cancer drug

The FDA’s approval of Circadian’s Investigational New Drug application for its antibody to treat cancer means the company is now well placed to begin the transition to a clinical development company.
Circadian Technologies: Van Leeuwenhoeck places share price target of $1.97

Van Leeuwenhoeck considers Circadian as "gravely undervalued at current share price of $0.50", and based on a sum-of-the-parts valuation, values the company at A$1.97 - around four times the last traded price - highlighting significant upside potential.
Circadian Technologies looks to royalties on cancer diagnostic test with Healthscope

Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the CUP test. The CUP test will be commercially available early next year, ringing in the transition for Circadian into a clinical development company.